Risks of Muscle Atrophy in Patients with Malignant Lymphoma after Autologous Stem Cell Transplantation.
hematologic malignancies
hematopoietic stem cell transplantation
muscle atrophy
sarcopenia
skeletal muscle index
Journal
Physical therapy research
ISSN: 2189-8448
Titre abrégé: Phys Ther Res
Pays: Japan
ID NLM: 101700769
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
04
2020
accepted:
25
09
2020
entrez:
13
5
2021
pubmed:
14
5
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Muscle atrophy is associated with autologous stem cell transplantation (ASCT)-related outcomes in patients with malignant lymphoma (ML). However, the impact of ASCT on muscle mass remains unclear in patients with ML. The aims of this study were to investigate changes in muscle mass and risk profiles for muscle atrophy after ASCT. We enrolled 40 patients with refractory ML (age 58 [20-74] years, female/male 16/24, body mass index (BMI) 21.1 kg/m Independent factors associated with a severe decrease rate of change in PMI were evaluated by decision-tree analysis, respectively. PMI was significantly decreased after ASCT (4.61 vs. 4.55 cm We demonstrated that muscle mass decreased after ASCT in patients with ML. Patients who received MCEC and patients with low BMI were at risk for a decrease in muscle mass.
Identifiants
pubmed: 33981529
doi: 10.1298/ptr.E10041
pmc: PMC8111411
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-76Informations de copyright
2021, JAPANESE PHYSICAL THERAPY ASSOCIATION.
Déclaration de conflit d'intérêts
There is no conflict of interest to disclose.
Références
Nutr Clin Pract. 2016 Feb;31(1):40-8
pubmed: 26703961
J Cancer Res Clin Oncol. 2017 Jun;143(6):1083-1092
pubmed: 28224299
Support Care Cancer. 2015 Apr;23(4):985-92
pubmed: 25256376
Int J Hematol. 2020 Feb;111(2):256-266
pubmed: 31732878
Dis Model Mech. 2013 Jan;6(1):25-39
pubmed: 23268536
Physiol Rev. 2009 Apr;89(2):381-410
pubmed: 19342610
Hepatol Res. 2019 Dec;49(12):1427-1440
pubmed: 31273895
Integr Cancer Ther. 2018 Jun;17(2):299-305
pubmed: 28617061
Intern Med. 2018 Jun 1;57(11):1503-1508
pubmed: 29321440
Am J Hematol. 2016 Oct;91(10):1002-7
pubmed: 27356783
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Nutr. 1997 May;127(5 Suppl):990S-991S
pubmed: 9164280
Oncol Nurs Forum. 2011 Mar;38(2):216-23
pubmed: 21356659
Ann Hematol. 2018 Aug;97(8):1445-1452
pubmed: 29610968
Spine J. 2018 Feb;18(2):285-293
pubmed: 28735766
Leuk Lymphoma. 2015;56(12):3456
pubmed: 26099488
Int J Hematol. 2016 Jun;103(6):676-85
pubmed: 27084252
Biol Blood Marrow Transplant. 2018 Aug;24(8):1741-1747
pubmed: 29496561
JCSM Rapid Commun. 2019 Jan-Jun;2(1):
pubmed: 31032492
Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):487-497
pubmed: 31116618
Hepatol Res. 2017 Mar;47(3):E22-E34
pubmed: 27062043
PLoS One. 2015 Oct 23;10(10):e0141364
pubmed: 26495973
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59
pubmed: 21694556
Cancers (Basel). 2019 Sep 04;11(9):
pubmed: 31487803
Einstein (Sao Paulo). 2016 Oct-Dec;14(4):580-584
pubmed: 28076611
PLoS One. 2019 Oct 9;14(10):e0223222
pubmed: 31596873
Anticancer Res. 2019 May;39(5):2241-2249
pubmed: 31092415
J Lasers Med Sci. 2019 Spring;10(2):125-130
pubmed: 31360381
PLoS One. 2018 Oct 10;13(10):e0204985
pubmed: 30303998
Med Sci Monit Basic Res. 2018 Feb 05;24:31-39
pubmed: 29398693
Nutr Cancer. 2017 Nov-Dec;69(8):1205-1210
pubmed: 28937794
Nutrition. 2016 Nov-Dec;32(11-12):1200-5
pubmed: 27292773
Asian Pac J Cancer Prev. 2015;16(18):8075-7
pubmed: 26745041
Int J Surg. 2016 Jun;30:136-42
pubmed: 27154615
Int J Hematol. 2019 Jun;109(6):673-683
pubmed: 30963469
J Natl Cancer Inst. 2019 Aug 1;111(8):837-844
pubmed: 30951603